Abstract |
The contribution of virologic and host factors to CD4 cell depletion associated with human immunodeficiency virus (HIV) type 1 was evaluated in children drawn from a larger efficacy trial of 2 doses of didanosine (ddI) monotherapy (Pediatric AIDS Clinical Trials Group 144). Thirty children, half with stable CD4 cell counts (non-progressors) and half with a marked decline in CD4 cells (progressors), were studied during 60-72 weeks of ddI therapy. The children were matched for age and CD4 cell counts at study entry. Three viral parameters, syncytium-inducing phenotype, higher virus load, and mutation in HIV-1 pol encoding the T69D/N mutation, were associated with disease progression. Disease progression was not associated with mutations in the reverse-transcriptase gene previously associated with resistance to ddI (L74V, K65R, or M184V). The selection of the T69D/N mutation in children with HIV-1 disease progression during ddI therapy suggests that this mutation confers a fitness advantage to the virus that may include resistance to ddI.
|
Authors | Willscott E Naugler, Florence H Yong, Vincent J Carey, Joan A Dragavon, Robert W Coombs, Lisa M Frenkel |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 185
Issue 4
Pg. 448-55
(Feb 15 2002)
ISSN: 0022-1899 [Print] United States |
PMID | 11865396
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anti-HIV Agents
- RNA, Viral
- Didanosine
|
Topics |
- Acquired Immunodeficiency Syndrome
(drug therapy, immunology, virology)
- Amino Acid Sequence
- Anti-HIV Agents
(therapeutic use)
- CD4 Lymphocyte Count
- Child, Preschool
- Didanosine
(therapeutic use)
- Drug Resistance, Viral
- Genes, pol
- Genotype
- HIV-1
(genetics, isolation & purification)
- Humans
- Molecular Sequence Data
- Mutation
- Phenotype
- RNA, Viral
(analysis)
- Viral Load
|